Please login to the form below

Not currently logged in
Email:
Password:

RA Patients

This page shows the latest RA Patients news and features for those working in and with pharma, biotech and healthcare.

FDA panel undermines Lilly and Incyte’s baricitinib hopes

FDA panel undermines Lilly and Incyte’s baricitinib hopes

The panel gave its blessing to the lower 2mg dose of the JAK inhibitor for adult patients with moderately-to-severely active RA who don’t respond to or cannot tolerate ... Lilly has put a brave face on the outcome, saying that it is “confident that

Latest news

  • AbbVie’s upadacitinib aces phase III trial AbbVie’s upadacitinib aces phase III trial

    AbbVie’s JAK1 inhibitor upadacitinib has proved more effective than the company’s widely-used TNF blocker Humira in a phase III trial in rheumatoid arthritis patients, without adding to a ... The results were achieved in patients with

  • AbbVie’s JAK inhibitor upadacitinib clears another phase III trial AbbVie’s JAK inhibitor upadacitinib clears another phase III trial

    symptoms and dampening down disease activity in RA patients compared to prior stable methotrexate therapy in the SELECT-MONOTHERAPY study. ... Its earlier trials in RA have compared the drug to placebo on top of methotrexate therapy.

  • Boehringer claims EU okay for Humira biosimilar Boehringer claims EU okay for Humira biosimilar

    Earlier this month Boehringer reported the results of the VOLTAIRE-RA in patients with moderate-to-severe rheumatoid arthritis, showing that Cyltezo was equivalent to $16bn-a-year Humira - the ... Nevertheless, the approval “marks a significant step

  • Boehringer builds evidence base for its Humira biosimilar Boehringer builds evidence base for its Humira biosimilar

    Biosimilars have potential cost benefits to the healthcare system and support affordable access to important biologic medicines for patients living with inflammatory disease like RA.”. ... The CHMP also recommended Cyltezo for paediatric patients, in

  • NICE backs Sanofi's Kevzara for routine NHS use NICE backs Sanofi's Kevzara for routine NHS use

    Peter Kuiper, Sanofi Genzyme ’s general manager for UK and Ireland, said: “This recommendation brings us one step closer to making Kevzara available to adult patients with severe RA and reinforces ... According to Arthritis Research UK, more than 400

More from news
Approximately 0 fully matching, plus 64 partially matching documents found.

Latest Intelligence

  • Pharma deals during February 2014 Pharma deals during February 2014

    Novo Nordisk conducted a phase I safety trial with anti-NKG2A in patients with RA, and will be advancing further development in inflammation, including anti-NKG2D1, which is currently undergoing phase ... DiaPep277R is currently in a phase III

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Lilly and NRAS launch arthritis awareness film campaign Lilly and NRAS launch arthritis awareness film campaign

    The film - called Behind The Smile - coincides with rheumatoid arthritis (RA) awareness week and encourages patients to talk to their healthcare professionals about their struggles and how the disease impacts their ... makes people with RA feel still

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Biosimilars in 2018: EU doctors’ perceptions of RA drug market

    Biosimilars in 2018: EU doctors’ perceptions of RA drug market. Published in pharmaphorum October 2015 by Laurent Chanroux. ... A panel of around 200 physicians treating RA across Europe (France, Germany, Italy, Spain and the UK) were asked how they

  • Removing the Roadblocks to Effective Patient Treatment

    However, we found RA patients wait an average of 18 months before presenting to a doctor. ... Roadblock 2: Diagnosis – Poor doctor relationship and ongoing anxiety. The relationship RA patients have with their rheumatologist is crucial in getting them

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics